Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire January 07, 2026 FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that it intends to offer and sell, subject to […]

Saratoga Investment Corp. Announces Fiscal Third Quarter 2026 Financial Results GlobeNewswire January 07, 2026 Reports 5.2% Increase in NII Per Share and 0.7% Increase in NAV from Previous Quarter, with NAV Per Share Remaining Stable Quarterly ROE of 13.5% Generates LTM ROE of 9.7% and Beats the BDC Industry Average of 6.6% NEW YORK, Jan.

Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 07, 2026 BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love,

LifeVantage Appoints Seasoned Technology Executive Mike Edwards as Chief Technology Officer to Drive Digital Innovation GlobeNewswire January 07, 2026 SALT LAKE CITY, Jan. 07, 2026 (GLOBE NEWSWIRE) — LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the addition of

Kura Sushi USA Announces Fiscal First Quarter 2026 Financial Results Company to host fireside chat and investor meetings at the 28th Annual ICR Conference GlobeNewswire January 07, 2026 IRVINE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) — Kura Sushi USA, Inc. (“Kura Sushi” or the “Company”) (NASDAQ: KRUS), a technology-enabled Japanese restaurant concept, today announced financial

BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes GlobeNewswire January 07, 2026 Decision ensures continued patient access to VENDAJE(R) and VENDAJE AC(R) POMPANO BEACH, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 07, 2026 CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation

Sanara MedTech Inc. Receives Innovative Technology Contract from Vizient for BIASURGE(R) Advanced Surgical Solution GlobeNewswire January 07, 2026 Contract awarded for products that bring improvement to the healthcare industry FORT WORTH, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology

Terrestrial Energy to Participate in the 28th Annual Needham Growth Conference GlobeNewswire January 07, 2026 CHARLOTTE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) — Terrestrial Energy Inc. (NASDAQ: IMSR) (“Terrestrial Energy” or “the Company”), a developer of small modular nuclear power plants using its Generation IV reactor technology, announced today that it will participate in the

Twelve Seas Investment Company III Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing January 9, 2026 GlobeNewswire January 07, 2026 New York, NY, Jan. 07, 2026 (GLOBE NEWSWIRE) — Twelve Seas Investment Company III (Nasdaq: TWLVU) (the “Company“) announced today that, commencing January 9, 2026, holders of the units sold